| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8958411 | Journal of Thoracic Oncology | 2018 | 7 Pages |
Abstract
Maintenance pembrolizumab did not appear to improve median PFS compared with the historical data. However, the 1-year PFS rate of 13% and OS rate of 37% suggest that a subset of patients did benefit from pembrolizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shirish M. MD, Nathan A. MD, PhD, Mary Jo MD, Balazs MD, Philip MD, James MD, Bryan MD, Ammar MD, Jaclyn BS, CCRP, Wei PhD, Cathy RN, Antoinette MD, Julie PhD, Gregory P. MD,